References
- Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton L J, III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–593
- Blom J W, Doggen C J, Osanto S, Rosendaal F R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722
- Heit J A, Silverstein M D, Mohr D N, Petterson T M, O'Fallon W M, Melton L J, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809–815
- Ambrus J L, Ambrus C M, Mink I B, Pickren J W. Causes of death in cancer patients. J Med 1975; 6: 61–64
- Gomes M P, Deitcher S R. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003; 17: 126–135
- Baron J A, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077–1080
- Prandoni P, Lensing A W, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488
- Geerts W H, Pineo G F, Heit J A, Bergqvist D, Lassen M R, Colwell C W, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126((Suppl 3))338S–400S
- Sallah S, Wan J Y, Nguyen N P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575–579
- Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005; 92: 1349–1351
- Ottinger H, Belka C, Kozole G, Engelhard M, Meusers P, Paar D, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54: 186–194
- Seifter E J, Young R C, Longo D L. Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat Rep 1985; 69: 1011–1013
- Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98: 1239–1242
- Levitan N, Dowlati A, Remick S C, Tahsildar H I, Sivinski L D, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
- Elting L S, Escalante C P, Cooksley C, Avritscher E B, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653–1661
- Lee A Y, Levine M N, Baker R I, Bowden C, Kakkar A K, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153
- Sorensen H T, Mellemkjaer L, Olsen J H, Baron J A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850